ClinicalTrials.gg
CompletedNCT03979937PRASEPTUpdated Mar 9, 2022

Development and Validation of a Simple Diagnostic Tool Predictive of the Aseptic Character of Joint Effusion

An observational study in Joint Effusion, Septic Arthritis and Arthritis, sponsored by Centre Hospitalier le Mans. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-09.

Sponsored by Centre Hospitalier le Mans · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
328
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Arthritis, Infectious with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Arthritis, Infectious · France.

Started
2020
the only one that year
Observational
9 of 13
2 open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Centre Hospitalier le Mans

Among the 13 studies in Arthritis, Infectious with a site in France, this one is the only one that started in 2020, is one of 9 observational ones, and was the 7th registered.

Arthritis, Infectious

51 studies on the registry are indexed under Arthritis, Infectious; 12 are open to participants now.

Browse Arthritis, Infectious studies →

Open to participants now

3 of the 13 studies in Arthritis, Infectious with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 7 Arthritis, Infectious studies recruiting now, 2 set no upper age limit and 5 stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Arthritis, Infectious with a site in France, or all of them as a file.
02

Study summary

Development and validation of a simple diagnostic tool predictive of the aseptic character of joint effusion in the primary care setting.

Read the detailed description

In accordance with guidelines and because of the potential gravity that this situation could represent, any joint effusion must be considered as a septic arthritis until proven otherwise, thus justifying an arthrocentesis and an adequate treatment. Nevertheless, because of epidemiology in primary care, this pragmatic attitude is quite commonly obscured and practices vary according to the experience of the doctor and his personal habits. As a result, the arthrocentesis is not commonly performed and anti-inflammatory treatment, whether based on NSAIDs or corticosteroids, is even sometimes administered to the patient despite the contrary guidelines. Although usually effective, this attitude is however not without risks. In this context, it seems interesting to develop a simple, reproducible and applicable diagnostic tool in a primary care setting for predicting the risk of septic arthritis.

This study is therefore aimed at the development and validation of a predictive score based on simple clinical and paraclinical data (such as the macroscopic appearance of the synovial fluid removed) in a patient with an effusion, whatever either the clinical presentation, whether isolated or integrated in a more complex clinical presentation, whether associated with locoregional inflammatory or general signs or not.

03

Conditions studied

  • Joint Effusion
  • Septic Arthritis
  • Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All adult patients presenting with at least one clinical joint effusion accessible to arthrocentesis, interesting a native non operated joint, without any general antibiotic therapy in the previous 15 days.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (age ≥ 18 years)
  • Hospitalized in the conventional hospitalization unit or day hospitalization unit or received in consultation within the Rheumatology or Infectious Diseases units at the Le Mans General Hospital
  • presenting at least one joint effusion at clinical examination
  • Interesting a native, nonoperated joint, accessible to a puncture based on clinical markers, determined by palpatory anatomy
  • Affiliated to social security
  • No opposition expressed after written information

Exclusion criteria

Exclusion Criteria:

  • General antibiotic therapy in progress or completed less than 15 days before
  • Failure to perform the arthrocentesis
  • Person subject to a legal protection measure, not allowing his compliance with the study
  • Participant already included in another study (exclusivity clause)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
328 participants (actual)
Target follow-up
10 Days
Patient registry
Yes

Interventions

  • ProcedureArthrocentesis

    Arthrocentesis to determine the nature of the effusion (septic or aseptic).

06

What researchers measure

Primary outcomes

  1. Presence of a septic arthritis

    Presence of more than 2000 cells/mL and bacterial growth in the articular fluid.

    Time frame: 10 days after the arthrocentesis.

07

Study locations

1 site
  • Centre Hospitalier Le Mans
    Le Mans, 72 000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Mar 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 10, 2019
StartActual
Feb 15, 2020
Primary completionActual
Mar 1, 2022
CompletionActual
Mar 1, 2022
Last update
Mar 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03979937
Lead sponsor
Centre Hospitalier le Mans
Responsible party
Sponsor
First posted
Jun 10, 2019
Start date
Feb 15, 2020
Primary completion
Mar 1, 2022
Completion
Mar 1, 2022
Last update
Mar 9, 2022

Study contacts

Emmanuelle Dernis, MD
principal investigator · Centre Hospitalier du Mans, Rheumatology Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion